| 1. | In the placebo group , no significant changes of symptoms were recorded
而在安慰剂组，实验前后没有观察到明显的症状改善。 |
| 2. | In contrast , all but one of the placebo - treated patients had deteriorated significantly
相对的是，安慰剂组一名患者出现了显著的恶化。 |
| 3. | Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group
治疗时间中位数在索拉非尼组为23周，在安慰剂组为19周。 |
| 4. | There was a significant faster dissolution of haematomas under the treatment with hirudoid in comparison to placebo
血肿的分解，喜疗妥组要显著快于安慰剂组。 |
| 5. | The duration of " off " time was significantly reduced in the 50 - mg and 100 - mg groups s placebo
50毫克组和100毫克组对比安慰剂组中的“药物无作用”时间显著减少。 |
| 6. | In the patients with incident amd , no difference was found between groups compared with placebo
结果发现，随机应用氧化剂组在amd发生率上与安慰剂组无统计学差异。 |
| 7. | Patients who supplemented with pycnogenol ? also had increased antioxidant levels compared to the placebo group
服用碧萝芷?治疗的患者的抗氧化水平也较安慰剂组有所提高。 |
| 8. | Results : there was significant improement in the primary endpoint in the 25 - mg and 50 - mg groups s placebo
结果：在用25毫克和50毫克患者对比安慰剂组中，试验主要终末点之间并无显著改善。 |
| 9. | The incidence of aderse effects was similar between the 25 - mg , 50 - mg , and placebo groups but higher in the 100 - mg group
在25毫克组， 50毫克组以及安慰剂组中的不良反应发生率相似，但在100毫克组中较高。 |
| 10. | Growth hormone was given for a minimum of 6 months , and the results were compared with no treatment or an inactive placebo
这些实验中给予生长激素治疗至少6个月，然后与未治疗组或安慰剂组比较治疗效果。 |
